Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Schizophrenia
Interventions
DRUG

Risperidone prolonged release

Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.

Trial Locations (5)

Unknown

Curitiba

Porto Alegre

Rio de Janeiro

Salvador

São Paulo

All Listed Sponsors
lead

Janssen-Cilag Ltd.

INDUSTRY

NCT01726335 - Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia | Biotech Hunter | Biotech Hunter